Startup profile · funding coverage
Scribe Therapeutics funding, valuation and investors
CRISPR enzyme engineering platform for in vivo genetic medicines.
Keep track of Scribe Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$20M · October 2020
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$20M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Alameda, California
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Scribe Therapeutics engineers CRISPR-based genetic medicines with proprietary nucleases and delivery systems for in vivo therapies. Spun out of research connected to Jennifer Doudna's lab at UC Berkeley, the Alameda, California company focuses on programmable gene editing beyond first-generation CRISPR tools. Scribe raised a $20M Series A in October 2020 led by Andreessen Horowitz and later partnered with Biogen on neurodegenerative disease programs.
Why Scribe Therapeutics is interesting
Industrialized CRISPR from Jennifer Doudna's orbit — a16z-led Series A before Biogen partnership on neurodegeneration programs.
Product & use cases
Scribe develops engineered CRISPR enzymes (including CasX-derived systems) and delivery platforms designed for in vivo editing — targeting diseases where conventional CRISPR tools lack efficiency or specificity.
- In vivo gene editing for neurodegenerative disease
- Proprietary nuclease design for therapeutic programs
- Biogen collaboration on CNS targets
- Platform licensing for pharma partners
Key facts
- Series A (Oct 2020): $20M led by a16z — a16z announcement
- Biogen collaboration on neurodegeneration programs — company press
- Spun from CRISPR research ecosystem connected to Jennifer Doudna
- Focus on in vivo gene editing with proprietary nucleases
Funding history (newest first)
Series A
2020-10 $20MSource: https://a16z.com/announcement/investing-in-scribe-therapeutics/
Investors in our directory
Funds linked from Scribe Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Novel enzyme engineering beyond SpCas9 — academic lineage from Doudna ecosystem with focus on in vivo delivery challenges.
In vivo CRISPR is crowded with public biotechs and platform startups. Scribe's bet is better enzymes + delivery for CNS and systemic editing. Biogen partnership validates pharma interest; clinical timelines remain long.
-
Intellia Therapeutics direct
In vivo CRISPR leader with clinical programs; public biotech.
-
Editas Medicine direct
CRISPR therapeutics with in vivo and ex vivo pipelines.
-
Beam Therapeutics adjacent
Base editing rather than nuclease cutting; overlapping genetic medicine space.
-
Mammoth Biosciences direct
Doudna-affiliated CRISPR diagnostics and therapeutics platform.
Notable stories
- Scribe emerged from the same CRISPR research community as Mammoth Biosciences, positioning on engineered enzymes rather than diagnostics.
- a16z's bio team led Series A as in vivo CRISPR moved from academic proof to pharma partnership stage.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Scribe Therapeutics's financing or category context.
FAQs about Scribe Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.